Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 21;15(16):4195. doi: 10.3390/cancers15164195

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure A5 — Correlation of the best response of DDR agents with tATM expression by Western blot analysis and the expression of downstream signalling marker scores of ATM and RAD51 in PDX models. (a,b) Correlation of tATM expression with the best response following AZD6738 monotherapy and combination with olaparib, respectively, (c,d) correlation of pRAD50 expression by IHC with the best response following AZD6738 monotherapy and combination with olaparib, respectively, (e,f) represents the correlation of pATM expression with best response following AZD6738 monotherapy and combination with olaparib, respectively, (g,h) represents the correlation of pKAP1 expression with the best response following AZD6738 monotherapy and combination with olaparib, respectively, (i,j) represents the correlation of the RAD51 foci score with the best response following AZD6738 monotherapy and combination with olaparib, respectively. Values of the best response represent the % TGI for AZD6738 monotherapy at 25 mg/kg BID 7ON 7OFF and the combination at 12.5 mg/kg BID with 100 mg/kg olaparib QD. Horizontal dotted lines indicate the best response of 50% TGI.